New characterization of patients with mild cognitive impairment with Alzheimer's markers could contribute to the success of clinical trials
Scientists were able to identify two distinct subgroups of the disease, a discovery that they believe could contribute to improving clinical trials, which are fundamental to the knowledge and treatment of this pathology that still has no cure.
the study involved national (68) and international (194) patients, with a total of 262 participants.
© CNC-UC | Rita Félix
An international research team, led by the University of Lisbon (UL) and the University of Coimbra (UC), conducted a study to better understand the biochemical profiles of patients diagnosed with mild cognitive impairment with Alzheimer's markers (MCI-AD). In this context, the scientists were able to identify two distinct subgroups of the disease, a discovery that they believe could contribute to improving clinical trials, which are fundamental to the knowledge and treatment of this pathology that still has no cure. (read more)